IPP Bureau
G 20: Medical Value Travel could be focused on maintaining, improving or restoring health through medical intervention: Dr V K Paul
By IPP Bureau - January 21, 2023
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
Innova Captab gets SEBI nod to raise funds via IPO
By IPP Bureau - January 20, 2023
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
Blue Jet Healthcare gets SEBI nod for IPO
By IPP Bureau - January 20, 2023
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Marengo Asia and Karkinos collaborate to cultivate comprehensive cancer care solutions in India
By IPP Bureau - January 20, 2023
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
Cheplapharm selects Generis’ CARA Life Sciences platform to unify their clinical processes
By IPP Bureau - January 20, 2023
Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes
ProBioGen’s vaccine production cell line AGE1.CR.pIX used for clinical production
By IPP Bureau - January 20, 2023
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
Krsnaa Diagnostics operationalized four diagnostics centres for Punjab Govt
By IPP Bureau - January 19, 2023
The company has operationalized diagnostics center at Ferozepur, Gurdaspur, Nawanshahr, and Kapurthala in Punjab.
Mandaviya urges stakeholders to partner with India to leverage opportunities at WEF Davos
By IPP Bureau - January 19, 2023
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
Lupin launches Sacubitril and Valsartan combination drug for heart failure patients
By IPP Bureau - January 19, 2023
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
USFDA completes inspection at APL HealthCare
By IPP Bureau - January 19, 2023
The company has been issued ‘Form 483’ with two observations
Stelis Biopharma’s flagship facility receives EIR from USFDA
By IPP Bureau - January 19, 2023
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets
By IPP Bureau - January 18, 2023
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
Glenmark to divest select dermatology brands for Rs. 340.48 Cr
By IPP Bureau - January 18, 2023
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
Panacea Biotec donates 125,000 doses of Easyfive-TT to Cuba
By IPP Bureau - January 18, 2023
This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba
Cipla launches Cippoint
By IPP Bureau - January 18, 2023
Point-of-Care solution to facilitate clinicians in quick and effective decision making
